Skip to main navigation
  • Skip to main content
  • Skip to footer
Scholar Rock

Scholar Rock - Utility Menu

  • Careers
  • Contact Us

Main navigation

  • Our Company
    • Management Team
    • Board of Directors
    • Partnering
    • Learn About Our Company
  • Our Science
    • Structural Insights & the Growth Factor Precursor
    • Platform
    • Publications & Posters
    • Learn About Our Science
  • Our Pipeline
    • Spinal Muscular Atrophy
    • Oncology
    • Fibrosis
    • Iron-Restricted Anemia
    • Clinical Trials
    • Learn About Our Pipeline
  • Patients & Families
  • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Committee Composition
      • Management Team
      • Board of Directors
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR

Breadcrumb

Home / Investors & Media

Investor overview

Explore Investors & Media

  • Investor Overview
  • Press Releases
    • Archived Press Releases
  • Events & Presentations
  • Corporate Governance
    • Committee Composition
    • Management Team
    • Board of Directors
  • Financials & Filings
    • SEC Filings
  • Stock Information
    • Historical Stock Lookup
    • Investment Calculator
    • Analyst Coverage
  • Investor FAQs
  • Contact IR

Corporate Profile

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our most advanced investigational product candidate, apitegromab (SRK-015), a selective inhibitor of the activation of the growth factor myostatin in skeletal muscle, is in development for the treatment of spinal muscular atrophy, or SMA. Apitegromab was evaluated in our TOPAZ Phase 2 proof-of-concept trial in patients with later-onset (Type 2 and Type 3) SMA and we shared positive 12-month top-line data demonstrating apitegromab’s therapeutic potential in April 2021. We plan to initiate the Phase 3 registrational trial by end of 2021. In addition, we are conducting our DRAGON Phase 1 proof-of-concept trial for SRK-181, a selective inhibitor of latent TGFβ1 activation, in patients with locally advanced and metastatic solid tumors. We believe SRK-181 has the potential to overcome resistance and meaningfully increase the number of patients who may benefit from checkpoint inhibitors, such as anti-PD-1 or anti-PD-L1 therapies.

Utilizing our proprietary platform, we are creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia.

News

View More Press Releases

April 10, 2021

Scholar Rock Presents Biomarker Strategy to Support the SRK-181 DRAGON Phase 1 Proof-of-Concept Trial at the American Association for Cancer Research Annual Meeting

Read This Press Release

April 6, 2021

Scholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

Read This Press Release

March 22, 2021

Scholar Rock Announces Publication of Preclinical Pharmacology, Pharmacokinetics, and Safety Profile of SRK-181 in the International Journal of Toxicology

Read This Press Release

Events

View More Events

April 6, 2021 8:00 AM EDT

12-Month Top-line Results of TOPAZ Phase 2 Trial

View This Event

March 1, 2021

Cowen 41st Annual Health Care Conference

View This Event

January 11, 2021 5:20 PM EST

39th Annual J.P Morgan Healthcare Conference

View This Event

  • RSS Feeds
  • Search

Footer

SCHOLAR ROCK
620 Memorial Dr 2nd Floor
Cambridge, MA 02139

MOVING EARLY 2021 TO
301 Binney Street, 3rd Floor
Cambridge, MA 02142

Phone: 857.259.3860
info@scholarrock.com

Contact Us

LinkedIn Twitter

Scholar Rock - Main navigation

  • Our Company
    • Management Team
    • Board of Directors
    • Partnering
    • Learn About Our Company
  • Our Science
    • Structural Insights & the Growth Factor Precursor
    • Platform
    • Publications & Posters
    • Learn About Our Science
  • Our Pipeline
    • Spinal Muscular Atrophy
    • Oncology
    • Fibrosis
    • Iron-Restricted Anemia
    • Clinical Trials
    • Learn About Our Pipeline
  • Patients & Families
  • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Committee Composition
      • Management Team
      • Board of Directors
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR
  • Community Guidelines
  • Expanded Access Policy
  • Terms of Use
  • Privacy Policy

Scholar Rock, Inc. © 2021 All Rights Reserved

    Scholar Rock - Main navigation

  • Our Company
    • Management Team
    • Board of Directors
    • Partnering
    • Learn About Our Company
  • Our Science
    • Structural Insights & the Growth Factor Precursor
    • Platform
    • Publications & Posters
    • Learn About Our Science
  • Our Pipeline
    • Spinal Muscular Atrophy
    • Oncology
    • Fibrosis
    • Iron-Restricted Anemia
    • Clinical Trials
    • Learn About Our Pipeline
  • Patients & Families
  • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Committee Composition
      • Management Team
      • Board of Directors
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR
  • Scholar Rock - Utility Menu

  • Careers
  • Contact Us